Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
17
×
boston blog main
boston top stories
17
×
life sciences
17
×
national blog main
national top stories
clinical trials
san francisco blog main
fda
san francisco top stories
new york blog main
san diego blog main
boston
indiana blog main
indiana top stories
new york top stories
san diego top stories
boulder/denver blog main
boulder/denver top stories
cancer
deals
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
eli lilly
europe blog main
national
roche
cancer drugs
europe top stories
novartis
alexion pharmaceuticals
What
drug
17
×
medicines
fda
cancer
ipo
new
genetic
therapeutics
approval
bio
brings
company
lead
muscle
research
biotech
blueprint
candidate
cholesterol
deal
designed
disease
diseases
dyne
dyne’s
expensive
long
market
marketing
medicine
million
patients
pharma
pharmaceuticals
plan
raised
rare
ready
ret
roche
Language
unset
17
×
Current search:
drug
×
biotech
×
unset
×
" life sciences "
×
" boston top stories "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)